Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.

ABSTRACT:

Background

Glioblastoma is a paradigm of cancer-associated immunosuppression, limiting the effects of immunotherapeutic strategies. Thus, identifying the molecular mechanisms underlying immune surveillance evasion is critical. Recently, the preferential expression of inhibitory natural killer (NK) cell receptor CD161 on glioma-infiltrating cytotoxic T cells was identified. Focusing on the molecularly annotated, large-scale clinical samples from different ethnic origins, the data presented here provide evidence of this immune modulator's essential roles in brain tumor biology.

Methods

Retrospective RNA-seq data analysis was conducted in a cohort of 313 patients with glioma in the Chinese Glioma Genome Atlas (CGGA) database and 603 patients in The Cancer Genome Atlas (TCGA) da

SUBMITTER: Di W 

PROVIDER: S-EPMC8819299 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature